Treatment, Prevention and Control

  • Adrian Mindel
Part of the The Bloomsbury Series in Clinical Science book series (BLOOMSBURY)


The recent development of specific safe and highly efficacious chemotherapy (in particular acyclovir) has revolutionised the treatment of HSV infections. Prior to the introduction of acyclovir, treatment was limited largely to the use of extremely toxic drugs for the management of severe infections and also symptomatic treatment for the milder manifestations of the various diseases (including labial and genital herpes). In this chapter I review the pharmacology, toxicity and clinical uses of antiviral drugs for the treatment of all aspects, of HSV infection, including labial, genital, ocular, disseminated, neonatal and cerebral infections. In addition to a consideration of antiviral chemotherapy, I also review the role of immune modulation, the potential production and efficacy of vaccines to prevent genital or oral herpes, the management of genital herpes in pregnancy, the importance of health education in the control of herpes, and the management of the psychological problems associated with genital herpes.


Herpes Simplex Genital Herpes Herpes Simplex Virus Infection Oral Acyclovir Recurrent Genital Herpes 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Adler MW, Mindel A (1983) Genital herpes — hype or hope. Br Med J 286: 1767–1768Google Scholar
  2. Adler MW, Mindel A (1985) Genital infection. Antiviral Chemotherapy and Interpheron. Br Med Bull 41: 361–366Google Scholar
  3. Anderson WA, Kilbourne ED (1961) Immunisation of mice with inactivated herpes simplex virus. Proc Soc Exp Biol Med 107: 518–520PubMedGoogle Scholar
  4. Andrews EB, Tilson HH, Hum BAL, Cordero JF and the Acyclovir in Pregnancy Advisory Committee (1988) Acyclovir in Pregnancy Registry: an observational epidemiologic approach. Am J Med 85 [suppl 2A]: 123–128PubMedGoogle Scholar
  5. Arita I, Fenner F (1985) Complicators of smallpox vaccination. In: Quinnan GU Jr (ed). Vaccinia viruses as vectors for vaccine antigens. Elsevier, New York pp 48–60Google Scholar
  6. Ashley RL, Corey L (1983) Development of antibodies to a herpes simplex virus type 2 (HSV 2) subunit vaccine in seropositive and seronegative volunteers. In: Abstracts of papers presented at an international herpes virus workshop, p 262Google Scholar
  7. Bauer DJ (1977) The specific treatment of virus disease. University Park Press, Baltimore, OH. Belsey EM, Adler MW (1978) Current approaches to the diagnosis of herpes genitalis. Br J Vener Dis 54: 115–117Google Scholar
  8. Binkin NJ, Koplan JP, Cates W (1984) Preventing neonatal herpes. The value of weekly viral cultures in pregnant women with recurrent genital herpes. JAMA 251: 2816–2821Google Scholar
  9. Blank H, Haines HG (1973) Experimental human reinfection with herpes simplex virus. J Invest Dermatol 61: 223–225PubMedGoogle Scholar
  10. Bodey GP, Gottlieb J, McCredie KB, Freireich EJ (1975) Adenine arabinoside in cancer chemotherapy. In: Pavan-Langston D, Buchanan RA, Alford CA, Jr (eds) Adenine arabinoside: an antiviral agent. Raven Press, New York pp 281–285Google Scholar
  11. Bouffat P, Saurat JH (1980) Isoprinosine as a therapeutic agent in recurrent mucocutaneous infections due to herpes virus. Int J Immunopharmacol 2: Abstract.Google Scholar
  12. Brigden D (1985) Skin infections. Antiviral chemotherapy and interferon. Br Med Bull 41: 357–360PubMedGoogle Scholar
  13. Brown ZA, Vontver LA, Benedetti J et al (1987) Effects on Infants of a first episode of genital herpes during pregnancy. N Engl J Med 317: 1246–1251PubMedGoogle Scholar
  14. Bryson YJ, Dillon M, Lovett M et al. (1983) Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. N Engl J Med 308: 916–921PubMedGoogle Scholar
  15. Buchanan RA, Hess F (1980) Vidarabine ( ViraA) pharmacology and clinical experience. Pharmacol Ther 8: 143–171Google Scholar
  16. Burns WH, Saral R, Santos GW, et al. (1982) Isolation and characterisation of resistant herpes simplex virus after acyclovir therapy. Lancet i: 421–423Google Scholar
  17. Cappel R, De Cuyper F, De Braekeeler J (1979) Antibody and cell mediated immunity to a DNA free herpes simplex subunit vaccine. Dev Biol Stand 43: 381–385PubMedGoogle Scholar
  18. Cappel R, Sprecher S, De Cuyper F, De Braekeleer J (1985) Clinical efficacy of a herpes simplex subunit vaccine. J Med Virol 16: 137–145PubMedGoogle Scholar
  19. Carter CA, Hartley CE, Skinner GRB, Turner SP, Easty DL (1981) Experimental ulcerative herpetic keratitis. IV. Preliminary observations on the efficacy of a herpes simplex subunit vaccine. Br J Ophthalmol 65: 679–682Google Scholar
  20. Chan WL (1983) Protective immunisation of mice with specific HSV 1 glycoproteins. Immunology 49: 343–352PubMedGoogle Scholar
  21. Cheng YC, Dutschman G, Fox JJ, Watanabe KA, Machida H (1981) Differential activity of potential antiviral nucleoside analogs on herpes simplex virus-induced and human cellular thymidine kinases. Antimicrob Agents Chemother 20: 420–423PubMedGoogle Scholar
  22. Chou S, Gallagher JG, Merigan TC (1981) Controlled clinical trial of intravenous acyclovir in heart-transplant patients with mucocutaneous herpes simplex infections. Lancet i: 1392–1394Google Scholar
  23. Coen CM, Schaffer PA (1981) Two distinct loci confer resistance to acycloguanosine in herpes simplex virus type 1. Proc Natl Acad Sci USA 77: 2265–2269Google Scholar
  24. Colin J, Tournoux A, Chastel C, Reynard G (1981) Superficial herpes simplex keratitis. Double blind comparative trial of acyclovir and idoxuridine. Nouv Press Med 10: 2969–2975Google Scholar
  25. Collum LMT, Benedict-Smith A, Hilary IB (1980) Randomised double blind trial of acyclovir and idoxuridine in dendritic corneal ulceration. Br J Ophthalmol 64: 766–769PubMedGoogle Scholar
  26. Collum LMT, Logan P, Ravenscroft T (1983) Acyclovir ( Zovirax) in herpetic disciform keratitis. Br J Ophthalmol 67: 115–118Google Scholar
  27. Committee on Fetus and Newborn (1980) Perinatal herpes simplex virus infections. Pediatrics 66: 147–148Google Scholar
  28. Corey L (1985) Genital Herpes. In: Holmes KK, Mardh P-A, Sparling PF, Wiesner PJ (eds) Sexually transmitted diseases. McGraw-Hill Book Company, New York pp 449–474Google Scholar
  29. Corey L (1986) Genital herpes simplex virus infections: natural history and therapy. In: Oriel J D, Harris JRW (eds) Recent advances in sexually transmitted diseases, vol 3, Churchill Livingstone, Edinburgh, pp 71–108Google Scholar
  30. Corey L, Holmes KK (1983) Genital herpes simplex virus infections: current concepts in diagnosis, therapy and prevention. Ann Intern Med 98: 973–983PubMedGoogle Scholar
  31. Corey L, Spear PG (1986) Infections with herpes simplex viruses. (Second of two parts.) N Engl J Med 314: 749–757Google Scholar
  32. Corey L, Reeves WC, Chiang WT et al. (1978) Ineffectiveness of topical ether for the treatment of herpes simplex virus infection. N Engl J Med 299: 237–239PubMedGoogle Scholar
  33. Corey L, Chiang WT, Reeves WC, Stamm WE, Brewar L, Holmes KK (1979) Effect of Isoprinosine on the cellular immune response in initial genital herpes virus infection. Clin Res 27: 41AGoogle Scholar
  34. Corey L, Nahmias AJ, Guinan ME, Benedetti JK, Critchlow CW, Holmes KK (1982) A trial of topical acyclovir in genital herpes virus infections. N Engl J Med 306: 1313–1319PubMedGoogle Scholar
  35. Corey L, Fife KH, Benedetti JK et al (1983) Intravenous acyclovir for the treatment of primary genital herpes. Ann Intern Med 98: 914–921PubMedGoogle Scholar
  36. Corey L, Mindel A, Fife KH, Sutherland S, Benedetti J, Adler MW (1985) Risk of recurrence after treatment of first episode genital herpes with intravenous acyclovir. Sex Transm Dis 12: 215–218PubMedGoogle Scholar
  37. Coster DJ, Jones BR, McGill J (1979) Treatment of amoeboid herpetic ulcers with adenine arabinoside or trifluorothymidine. Br J Ophthalmol 63: 418–421PubMedGoogle Scholar
  38. Coster DJ, Jones BR, McGill J (1979) Treatment of amoeboid herpetic ulcers with adenine arabinoside or trifluorothymidine. Br J Ophthalmol 63: 418–421PubMedGoogle Scholar
  39. Coster DJ, Wilhelmus KR, Michaud R, Jones BR (1983) A comparison of acyclovir and idoxuridine in treatment for ulcerative herpetic keratitis. Br J Ophthalmol 95: 175–181Google Scholar
  40. Cremer KJ, Mackett M, Wohlenberg C, Notkins AL, Moss B (1985) Vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D prevents latent herpes in mice. Science 228: 737–740PubMedGoogle Scholar
  41. Crumpacker CS, Schnipper LE, Marlow SI, Kowalsky PN, Hershey BJ, Levin MJ (1982) Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir. N Engl J Med 306: 343–346PubMedGoogle Scholar
  42. Csonka GW, Tyrrell DAJ (1984) Treatment of herpes genitalis with carbenoxolone and cicloxolone cream: a double blind placebo controlled clinical trial. Br J Vener Dis 60: 178–181PubMedGoogle Scholar
  43. Dargan DJ, Subak-Sharpe JH (1986) The antiviral activity against herpes simplex virus of the triterpenoid compounds carbenoxolone sodium and cicloxolone sodium. J Antimicrob Chemother 18 [suppl B]: 185–200.PubMedGoogle Scholar
  44. Dawson CR (1984) Ocular herpes simplex virus infections. Clin Dermatol 2: 56–66PubMedGoogle Scholar
  45. De Clercq E (1985) Recent trends and development in antiviral chemotherapy. In Proceedings of the First International TNO Conference on Antiviral Research; Rotterdam. Antiviral Res [Suppl 1 ): 11–19Google Scholar
  46. De Clercq E, Descamps J, De Somer P, Barr PJ, Jones AS, Walker RT (1979) (E)-5-(2-bromovinyl)-2’-deoxyuridine: a potent and selective anti-herpes agent. Proc Natl Acad Sci USA 76: 2947–2951PubMedGoogle Scholar
  47. Derman RJ (1986) Counselling the herpes genitalis patient. J Reprod Med 31 [suppl]: 439–444PubMedGoogle Scholar
  48. Douglas JM, Critchlow C, Benedetti J et al. (1984) A double blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N Engl J Med 310: 1551–1556PubMedGoogle Scholar
  49. Eisenberg JR, Cerini PC, Heilman CJ, et al (1985) Synthetic glycoprotein D-related peptides protect mice against herpes simplex virus challenge. J Virol 56: 1014–1017PubMedGoogle Scholar
  50. Elion GB (1982) Mechanism of action and selectivity of acyclovir. Am J Med 73 [suppl 1A]: 7–13PubMedGoogle Scholar
  51. Ertl HCJ, Finberg RW (1984) Sendai virus-specific T-cell clones: induction of cytolytic T cells by an anti-idiotype antibody directed against a helper T-cell clone. Proc Natl Acad Sci USA 81: 2850–2854PubMedGoogle Scholar
  52. Farrell RG, Nesland RS (1977) Topical ethyl ether therapy of herpes simplex infections. J Am Coll Emerg Physic 6: 372–373Google Scholar
  53. Fawcett HA, Wansbrough-Jones MH, Clark AE, Leigh IM (1983) Prophylactic topical acyclovir for frequent recurrent herpes simplex infection with and without erythema multiforme. Br Med J 287: 98–99Google Scholar
  54. Field HJ, Darby G, Wildy P (1980) Isolation and characterization of acyclovir-resistant mutants of herpes simplex virus. J Gen Virol 49: 115–124PubMedGoogle Scholar
  55. Fiddian AP, Ivanyi L (1983) Topical acyclovir in the management of recurrent herpes labialis. Br J Dermatol 109: 321–326PubMedGoogle Scholar
  56. Fiddian AP, Yeo JM, Stubbings R, Dean D (1983a) Successful treatment of herpes labialis with topical acyclovir. Br J Med 286: 1699–1700Google Scholar
  57. Fiddian AP, Kinghorn GR, Golmeier D et al. (1983b) Topical acyclovir in the treatment of genital herpes: a comparison with systemic therapy. J Antimicrob Chemother. 12 [suppl B]: 67–77PubMedGoogle Scholar
  58. Furman PA, St Clair MH, Fyfe JA, Rideout JL, Keller PM, Elion GB (1979) Inhibition of herpes simplex virus induced DNA polymerase activity and viral DNA replication by 9-(2- hydroxyethoxymethyl)guanine and its triphosphate. J Med Virol 32: 72–77Google Scholar
  59. Fyfe JA (1982) Differential phosphorylation of (E)-5-(2-bromovinyl-2’-deoxyuridine monophosphate by thymidylate kinases from herpes simplex viruses types 1 and 2 and varicella zoster virus. Mol Pharmacol 21: 432–437PubMedGoogle Scholar
  60. Galli M, Lazzarin A, Moroni M, Zanussi C (1982) Inosiplex in recurrent herpes simplex infections. Lancet ii: 331–332Google Scholar
  61. Gaub J, Pedersen C, Poulson A-G, et al (1987) The effect of Foscarnet (phosphonoformate) on human immunodeficiency virus isolation, T-cell subsets and lymphocyte function in AIDS patients. AIDS 1: 27–33Google Scholar
  62. Glezerman M, Lunenfeld E, Cohen V, et al. (1988) Placebo-controlled trial of topical interferon in labial and genital herpes. Lancet i: 150–152Google Scholar
  63. Gold D, Benedetti J, Corey L (1986) Topical surfactant therapy for recurrent herpes simplex infection. Lancet ii: 283 Google Scholar
  64. Goldberg CB (1986) Controlled trial of “Intervir-A” in herpes simplex virus infection. Lancet i: 703–706Google Scholar
  65. Goldman L (1961) Reactions of an auto inoculation for recurrent herpes simplex. Arch Dermatol 84: 1025–1026PubMedGoogle Scholar
  66. Halsos AM, Salo OP, Lassus A, et al. (1985) Oral acyclovir suppression of recurrent genital herpes: a double-blind, placebo controlled cross-over study. Acta Derm Venereol (Stockh) 65: 59–63Google Scholar
  67. Hann IM, Prentice HG, Blacklock HA, et al (1983) Acyclovir prophylaxis against herpes virus infection in severely immunocompromised patients: randomised double blind trial. Br Med J 287: 384–388Google Scholar
  68. Heidelberger C, King D (1979) Trifluorothymidine. Pharmacol Ther 6: 427–442Google Scholar
  69. Herrman EC Jr (1961) Plaque inhibition test for detection of specific inhibitors of DNA containing viruses. Proc Soc Exp Biol Med 107: 142–145PubMedGoogle Scholar
  70. Hilleman MR, Larson VH, Lehman ED, et al (1981) Sub-unit herpes simplex virus-2 vaccines In: Nahmias AJ, Dowdle WR, Schinazi RF (eds) The human herpesviruses. Elsevier, New York, pp 503–506Google Scholar
  71. Huang ES, Huang CH, Huong SM, Selgrade M (1976) Preferential inhibition of herpes group viruses by phosphonoacetic acid: effect on virus DNA synthesis and virus-induced DNA polymerase activity. Yale J Biol Med 49: 93–98PubMedGoogle Scholar
  72. Jones BR, Coster DJ, Falcon MG, Cantell K (1976) Topical therapy of ulcerative herpetic keratitis with human interferon. Lancet ii: 128Google Scholar
  73. Kaerner HC, Schroder CH, Ott-Hartmann A, Kummel G, Kircher H (1983) Genetic variability of herpes simplex virus: development of a pathogenic variant during passaging of a non-pathogenic herpes simplex virus type 1 virus strain in mouse brain. J Virol 46: 83–93PubMedGoogle Scholar
  74. Kennedy RC, Dreesman GR (1984) Enhancement of the immune response to hepatitis B surface antigen. In vivo administration of anti-idiotype induces anti-HBs that express a similar idiotype. J Exp Med 159: 655–665Google Scholar
  75. Kinghorn GR, Turner EB, Barton IG, Potter CW, Burke CA, Fiddian AP (1983) Efficacy of topical acyclovir cream in first and recurrent episodes of genital herpes. Antiviral Res 3: 291–301PubMedGoogle Scholar
  76. Kinghorn GR, Jeavons M, Rowland M et al. (1985) Acyclovir prophylaxis of recurrent genital herpes: a randomised placebo controlled crossover study. Genitourin Med 61: 387–390PubMedGoogle Scholar
  77. Kit S, Quavi H, Dubbs DR, Otsuka H (1983) Attenuated marmoset herpes virus isolated from recombinants of virulent marmoset herpes virus and hybrid plasmids. J Med Virol 12: 25–36PubMedGoogle Scholar
  78. Kitces EN, Morahan PS, Tew JG, Murray BK (1977) Protection from oral herpes simplex virus infection by a nucleic acid-free virus vaccine. Infect Immun 16: 955–960PubMedGoogle Scholar
  79. Klein RJ, Buimovici-Klein E, Mosur H, Moucha R, Hilfenhaus J (1981) Efficacy of a virion envelope herpes simplex virus against experimental skin infections in hairless mice. Arch Virol 68: 73–80PubMedGoogle Scholar
  80. Kutinova L, Vonka V, Stichtova V (1980) Immunogenicity of subviral herpes simplex virus preparations: protection of mice against intraperitoneal infection with live virus. Acta Virol (English Edition) 24: 391–398Google Scholar
  81. La Lau C, Oosterhuis JA, Versteeg J, et al. (1982) Acyclovir and trifluorothymidine in herpetic keratitis: a multicentre trial. Br J Opthalmol 66: 506–508Google Scholar
  82. Lasky LA, Dowbenko D, Simonson C, Berman PW (1984) Production of an HSV subunit vaccine by genetically engineered mammalian cell lines. In: Chanock RM, Lerner RA (eds) Modern approaches to vaccines: molecular and chemical basis of virus virulence and immunogenicity. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY pp 189–194Google Scholar
  83. Lazar MP (1956) Vaccination for recurrent herpes simplex infection: initiation of a new disease site following the use of unmodified material containing the live virus. Arch Dermatol 73: 70–71Google Scholar
  84. Lee FK, Coleman RM, Pereira L, Bailey PD, Tatsuno M, Nahmias AJ (1985) Detection of herpes simplex virus type 2-specific antibody with glycoprotein G. J Clin Microbiol 22: 641–644PubMedGoogle Scholar
  85. Lee FK, Pereira L, Griffin C, Reid E, Nahmias A (1986) A novel glycoprotein for detection of herpes simplex virus type 1 specific antibodies. J Virol Methods 14: 111–118PubMedGoogle Scholar
  86. Leigh IM (1988) The management of nongenital herpes simplex virus infection in immunocompetent patients. Am J Med 85 [suppl 2A]: 34–38PubMedGoogle Scholar
  87. Levaditi C (1926) L’herpes et le zona. Masson, Paris.Google Scholar
  88. Long D, Madara TJ, Ponce de Leon M, Cohen GH, Montgomery PC, Eisenberg RJ (1985) Glycoprotein D protects mice against lethal challenge with herpes simplex virus types 1 and 2. Infect Immun 43: 761–764Google Scholar
  89. Macher E (1957) Zur Behandlung des chronisch-rezivienrenden herpes simplex. Z Hautkr 23: 18–22Google Scholar
  90. Mao JCH, Robishaw EE (1975) Mode of inhibition of herpes simplex virus DNA polymerase by phosphonoacetate. Biochemistry 14: 5475–5479PubMedGoogle Scholar
  91. McCulley JP, Binder PS, Kaufman HE, O’Day DM, Poirier RH (1982) A double blind multicenter clinical trial of acyclovir vs idoxuridine for treatment of epithelial herpes simplex keratitis. Opthalmology 89: 1195–1200Google Scholar
  92. McGill JI (1984) Antiviral treatment of herpes simplex stroma disease. In: Maudgal P (ed) Herpetic eye disease. Junk, Berlin pp 217–221Google Scholar
  93. McGill J, Scott GM (1985) Viral keratitis. Br Med Bull 41: 351–356PubMedGoogle Scholar
  94. McGill J, Tormey P, Walker CD (1981) Comparative trial of acyclovir and adenine arabinoside in the treatment of herpes simplex corneal ulcers. Br J Opthalmol 65: 610–613Google Scholar
  95. McClaren C, Corey L, Dekker C, Barry DW (1983) In vitro sensitivity to acyclovir in genital herpes simplex viruses from acyclovir treated patients. J Infect Dis 148: 868–875Google Scholar
  96. Meignier B (1985) Vaccination against herpes simplex virus infections. In: Roizman B, Lopez C (eds) The herpes viruses, vol 4, Plenum Press, New York pp 265–296Google Scholar
  97. Mertz GJ, Critchlow CW, Benedetti J, et al (1984) Double blind placebo controlled trial of oral acyclovir in first episode genital herpes simplex virus infection. JAMA 252: 1147–1151Google Scholar
  98. Mertz GJ, Jones CC, Mills J et al (1988) Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection. A multicenter double-blind trial. JAMA 260: 201–266Google Scholar
  99. Meyers JD, Wade JC, Mitchell CD, et al. (1982) Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host. Am J Med 73: 229–235PubMedGoogle Scholar
  100. Meyrick Thomas RH, Dodd HJ, Yeo JM, Kirby JP (1985) Oral acyclovir in the suppression of recurrent non-genital herpes simplex virus infection. Br J Dermatol 113: 731–735Google Scholar
  101. Miller WH, Miller RL (1980) Phosphorylation of acyclovir (acycloguanosine) monophosphate by GMP kinase. J Bio Chem 255: 7204–7207Google Scholar
  102. Mindel A (1984) Treatment and prevention of herpes genital infection. J Antimicrob Chemother 14 [suppl A]: 75–83PubMedGoogle Scholar
  103. Mindel A, Carney O (1988) Acyclovir malabsorption. Br Med J 296: 1605Google Scholar
  104. Mindel A, Sutherland S (1983) Genital herpes - the disease and its treatment including intravenous acyclovir. J Antimicrob Chemother 12 [suppl B]: 51–59PubMedGoogle Scholar
  105. Mindel A, Adler MW, Sutherland S, Fiddian AP (1982) Intravenous acyclovir treatment for primary genital herpes. Lancet i: 697–700 PubMedGoogle Scholar
  106. Mindel A, Weller IVD, Faherty A, et al. (1984) Prophylactic oral acyclovir in recurrent genital herpes. Lancet ii: 57–59PubMedGoogle Scholar
  107. Mindel A, Weller IVD, Faherty A, Sutherland S, Fiddian AP, Adler MW (1986) Acyclovir in first attacks of genital herpes and prevention of recurrences. Genitourin Med 62: 28–32PubMedGoogle Scholar
  108. Mindel A, Kinghorn G, Allason-Jones E, et al. (1987) Treatment of first-attack genital herpes acyclovir versus inosine pranobex. Lancet i: 1171–1173PubMedGoogle Scholar
  109. Mindel A, Faherty A, Carney O, Patou G, Williams P (1988) The efficacy, dosage and safety of longterm suppressive acyclovir for the treatment of recurrent genital herpes. Lancet i: 926–928PubMedGoogle Scholar
  110. Mindel A, Carney O, Sonnex C, Freris M, Patou G, William P (1989) Suppression of frequently recurring genital herpes. Acyclovir versus inosine pranobex. Genitourin Med 65: 103–105Google Scholar
  111. Mitchell CD, Bean B, Gentry SR, Groth KE, Boen JR, Balfour HH (1981) Acyclovir therapy for mucocutaneous herpes simplex infections in immunocompromised patients. Lancet i: 1389–1392PubMedGoogle Scholar
  112. Mocarski ES, Post LE, Roizman B (1980) Molecular engineering of the herpes simplex virus genome: insertion of a second L-S junction into the genome causes additional genome inversion. Cell 22: 243–255PubMedGoogle Scholar
  113. Muller WEG (1977) Rational design of arabinosyl nucleosides as antitumor and antiviral agents. Jpn J Antibiot 30 [suppl]: S104–S120Google Scholar
  114. Muller WEG (1979) Mechanism of action and pharmacology: chemical agents. In: Galasso G J, Merigan TC, Buchanan RA (eds) Antiviral agents and viral diseases of man. 1st edn, Raven Press, New York, pp 77–149Google Scholar
  115. Nahmias AJ, Keyserling HL (1984) Neonatal herpes simplex in context of the Torch complex. In: Holmes KK, Mardh P, Sparling PF, Wiesner PJ (eds) Sexually transmitted diseases. McGraw- Hill Book Company, New York, pp 816–826Google Scholar
  116. Nahmias AJ, Josey WE, Naib ZM, Freeman MG, Fernandez RJ, Wheeler JH (1971) Perinatal risk associated with maternal genital herpes simplex virus infection. Am J Obstet Gynecol 110: 825–837PubMedGoogle Scholar
  117. Nasemann TH, Wassilew SW (1979) Vaccination for herpes simplex genitalis. Br J Vener Dis 55: 121–122PubMedGoogle Scholar
  118. Nilsen AE, Aasen T, Halsos AM et al. (1982) Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes. Lancet ii: 571–573PubMedGoogle Scholar
  119. Oberg B (1983) Antiviral effects of phosphonoformate (PFA, Foscarnet sodium). Pharmacol Ther 19: 387–415Google Scholar
  120. Overall JC Jr (1984) Dermatologic viral diseases. In: Galasso GJ, Merigan TC, Buchanan RA (eds) Antiviral agents and viral diseases of man, 2nd edn, Raven Press, New York, pp 247–312Google Scholar
  121. Panscherewski D, Rhode B (1957) Zur Serologic und Therapie des Herpes Simplex recidivans. Hautarzt 13: 275–278Google Scholar
  122. Paoletti E, Panicali D (1984) Genetically engineered pox viruses as live recombinant vaccines. In: Chanock RM and Lerner RA (eds) Modern approaches to vaccines — molecular and chemical basis of virus virulence and immunospecificity. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp 295–299Google Scholar
  123. Partridge M, Poswillo DE (1984) Topical carbonoxolone sodium in the management of herpes simplex infections. Br J Oral Maxillofac Surg 22: 138–145PubMedGoogle Scholar
  124. Patterson A, Jones BR (1967) The management of ocular herpes. Trans Opthalmol Soc UK 87: 59–84Google Scholar
  125. Pavan-Langston D (1984) Ocular viral diseases. In: Galasso GJ, Merigan TC, Buchanan RA (eds) Antiviral agents and viral diseases of man, 2nd edn. Raven Press, New York, pp 207–245Google Scholar
  126. Pazin GJ, Harger JH (1986) Management of oral and genital herpes simplex virus infection: diagnosis and treatment. DM 32: 725–824PubMedGoogle Scholar
  127. Post LE, Roizman B (1981) A generalised technique for deletion of specific genes in large genomes: alpha gene 22 of herpes simplex virus 1 is not essential for growth in cell culture. Cell 25: 227–232PubMedGoogle Scholar
  128. Post LE, Mackem S, Roizman B (1981) The regulation of alpha genes of herpes simplex virus: expression of chimeric genes produced by fusion of thymidine kinase with a gene promoters. Cell 34: 555–556Google Scholar
  129. Poswillo DE, Roberts GJ (1981) Topical carbonoxolone for orofacial herpes simplex infection. Lancet ii: 143–144PubMedGoogle Scholar
  130. Price RW, Walz MA, Wohlenberg C, Notkins AL (1975) Latent infection of sensory ganglia with herpes simplex virus: efficacy of immunisation. Science 188: 938–940PubMedGoogle Scholar
  131. Prober CG, Sullender WM, Yasukawa LL, Au DS, Yeager AA, Arvin AM (1987) Low risk of herpes simplex virus infections in neonates exposed to the virus at the time of vaginal delivery to mothers with recurrent genital herpes simplex virus infection. N Engl J Med 316: 240–244PubMedGoogle Scholar
  132. Prusoff WH (1959) Synthesis and biological activities of iododeoxyuridine, an analog of thymidine. Biochem Biophys Acta 132: 295–296Google Scholar
  133. Prusoff WH, Goz B (1975) Halogenated pyrimidine deoxyribonucleosides. In: Eichler O, Herken F H, Welch AD (eds) Handbook of experimental pharmacology, vol 38, part 2. Springer, Berlin, Heidelberg, New York, pp 272–347Google Scholar
  134. Prusoff WH, Ward DC (1976) Commentary: nucleosides analogs with antiviral activity. Biochem Pharmacol 25: 1233–1239PubMedGoogle Scholar
  135. Prusoff WH, Chen MS, Fischer PH, et al. (1979) Antiviral iodinated pyrimidine deoxyribonucleosides: 5-iodo-2’-deoxyuridine; 5-iodo-2’-deoxycytidine; 5-iodo-5’-amino-2’,5’-dideoxyuridine. Pharmacol Ther 7: 1–34PubMedGoogle Scholar
  136. Raborn GW, McGaw WT, Grace M, Percy J (1988) Treatment of herpes labialis with acyclovir: review of three clinical trials. Am J Med 85 [suppl 2A]: 39–42PubMedGoogle Scholar
  137. Reagan KJ, Wunner WH, Koprowski H (1985) Viral antigen-independent immunization: induction by anti-idiotypic antibodies of neutralizing antibodies to defined epitopes on rabies virus glycoprotein,. In: Dreesman GR, Bronson JG, Kennedy RC (eds) High technology route to virus vaccines. Am Soc Microbiol, Washington DC, pp 117–124Google Scholar
  138. Reichman RC, Badger GJ, Mertz GJ, et al. (1984) Treatment of recurrent genital herpes simplex infection with oral acyclovir: a controlled trial. JAMA 251: 2103–2107PubMedGoogle Scholar
  139. Roizman B, Arsenakis M (1985) Genetic engineering of herpes simplex virus genomes for attentuation and expression of foreign genes. In: Quinnan G U Jr (ed). Vaccinia viruses as vectors for vaccine antigens. Elsevier, New York, pp 211–223Google Scholar
  140. Sacks SL, Portnoy J, Lawee D et al. (1987) Clinical course of recurrent genital herpes and treatment with Foscarnet cream: results of a Canadian multicenter trial. J Infect Dis 155: 178–186PubMedGoogle Scholar
  141. Salo O, Lassus A (1983) Treatment of recurrent genital herpes with isoprinosine. Eur J Sex Trans Dis 1: 101–105Google Scholar
  142. Salo OP, Lassus A, Hovi R, Fiddian AP (1983) Double blind placebo controlled trial of oral acyclovir in recurrent genital herpes. Eur J Sex Trans Dis 1: 95–98Google Scholar
  143. Saral R, Burns WH, Laskin OL, Santos GW, Lietman PS (1981) Acyclovir prophylaxis of herpes simplex virus infections. A randomised, double-blind, controlled trial in bone-marrow transplant recipients. N Engl J Med 305: 63–67Google Scholar
  144. Saral R, Ambinder RF, Burns WH et al. (1983) Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. Ann Intern Med 99: 773–776PubMedGoogle Scholar
  145. Schadelin J, Schilt U, Rohner M (1988) Prevention of labialis following trigeminal surgery. Am J Med 85 [suppl 2A]: 46–48PubMedGoogle Scholar
  146. Schinazi RF, Del Bene V, Taylor Scott R, Dudley-Thorpe J (1986) Characterisation of acyclovir resistant and sensitive herpes simplex viruses isolated from a patient with an acquired immune deficiency. J Antimicrob Chemother 18 [suppl B]: 127–134PubMedGoogle Scholar
  147. Schnipper LE, Crumpacker CS (1980) Resistance of herpes simplex virus to acycloguanosine: role of viral thymidine kinase and DNA polymerase loci. Proc Natl Acad Sci USA 77: 2270–2273PubMedGoogle Scholar
  148. Scriba M (1978) Protection of guinea pigs against primary and recurrent genital herpes infection by immunization with live heterologous or homologous herpes simplex virus: implication for a herpes virus vaccine. Med Microbiol Immunol 166: 63–69PubMedGoogle Scholar
  149. Sege K, Peterson PA (1978) Use of anti-idiotypic antibodies as cell surface receptor probes. Proc Natl Acad Sci USA 75: 2443–2447PubMedGoogle Scholar
  150. Sharpe AH, Gaulton GN, McDade KK, Fields BN, Greene MI (1984) Syngeneic monoclonal antiidiotype can induce cellular immunity to reovirus. J Exp Med 160: 1195–1205PubMedGoogle Scholar
  151. Shaw M, King M, Best JM, Banatvala JE, Gibson JR, Klaber MR (1985) Failure of acyclovir cream in treatment of recurrent herpes labialis. Br Med J 291: 7–9Google Scholar
  152. Sibrack CD, Gutman LT, Wilfert CM, et al. (1982) Pathogenicity of acyclovir-resistant herpes simplex virus type 1 from an immunodeficient child. J Infect Dis 146: 673–682PubMedGoogle Scholar
  153. Skinner G, Buchan A, Hartley CE, Turner SP, William DR (1980) The preparation, efficacy and safety of “antigenoid” vaccine NFU(S-L+) MRC towards prevention of herpes simplex virus infections in human subjects. Med Microbiol Immunol 169: 39–51PubMedGoogle Scholar
  154. Skinner GRB, Woodman G, Hartley CE, et al. (1982a) Early experience with “antigenoid” vaccine Ac NFU (S-) MRC towards prevention and modification of herpes genitalis. Dev Biol Stand 52: 333–344PubMedGoogle Scholar
  155. Skinner GRB, Woodman GB, Hartley CE, et al. (1982b) Preparation and immunogenicity of vaccine Ac NFU (S-) MRC towards the prevention of herpes genitalis. Br J Vener Dis 58: 381–386PubMedGoogle Scholar
  156. Skinner GRB, Buchan A, Durham J et al. (1987) Role of bovine mammillitis virus towards preparation of an alternative vaccine against herpes simplex virus infections of human subjects. Vaccine 5: 55–59PubMedGoogle Scholar
  157. Skoldenberg B, Forsgren M, Alestig K, et al. (1984) Acyclovir versus vidarabine in herpes simplex encephalitis. Randomised multicentre study in consecutive Swedish patients. Lancet ii: 707–711Google Scholar
  158. Slichtova V, Kutinova L, Vonka V (1980) Immunogenicity of subviral herpes virus type 1 preparation: protection of mice against intradermal challenge with type 1 and type 2 viruses. Arch Virol 66: 207–214PubMedGoogle Scholar
  159. Spruance SL (1988) Cutaneous herpes simplex virus lesions induced by ultraviolet radiation: a review of model systems and prophylactic therapy with oral acyclovir. Am J Med 85 [suppl 2A]: 43–45PubMedGoogle Scholar
  160. Spruance SL, Schnipper LE, Overall JC Jr., et al. (1982) Treatment of herpes simplex labialis with topical acyclovir in polyethylene glycol. J Infect Dis 146: 85–90PubMedGoogle Scholar
  161. Straus SE, Takiff HE, Seidlin M, et al. (1984) Suppression of frequently recurring genital herpes. A placebo controlled double blind trail of oral acyclovir. N Engl J Med 316: 1545–1550Google Scholar
  162. Sugar J, Kaufman HE (1973) Halogenated pyrimidines in antiviral therapy. In: Carter W A (ed) Selective inhibition of viral functions. CRC Press, Cleveland, OH, pp 295–311Google Scholar
  163. Sullivan-Bolyai J, Hill HF, Wilson C, Corey L (1983) Neonatal herpes simplex virus infection in King County, Washington. Increasing incidence and epidemiologic correlates. JAMA 250: 3059–3062Google Scholar
  164. Taylor CA, Hendley SO, Greer KE, Gwaltney JM (1977) Topical treatment of herpes labialis with chloroform. Arch Dermatol 113: 1550–1552PubMedGoogle Scholar
  165. Thin RN, Nabarro JM, Davidson Parker J, Fiddian AP (1983) Topical acyclovir in the treatment of initial genital herpes. Br J Vener Dis 59: 116–119PubMedGoogle Scholar
  166. Thin RN, Jeffries, DJ, Taylor PK, et al. (1985) Recurrent genital herpes suppressed by oral acyclovir: a multicentre double-blind trial. J Antimicrob Chemother 16: 219–226PubMedGoogle Scholar
  167. Thompson RL, Stevens J (1983) Replication of body temperature selects a neurovirulent herpes simplex virus type 2. Infect Immun 41: 855–857PubMedGoogle Scholar
  168. Thompson TA, Murray BK, Morahan PS, Cline P (1981) Protective studies on several herpes simplex type 1 vaccine preparations in a mouse labial infection model. In: Nahmias AJ, Dowdle WR, Schinazi RF (eds) The human herpesviruses. New York, Elsevier, pp 649–650Google Scholar
  169. Thompson TA, Hilfenhaus J, Mosar H, Morahan PS (1983) Comparison of effects of adjuvants in efficacy of virion envelope herpes simplex virus vaccine against labial infection of Balb/c mice. Infect Immun 41: 556–562Google Scholar
  170. Thornton B, Griffiths JB, Walkland A (1982) Herpes simplex vaccine using cell membrane associated antigen in animal models. Dev Biol Stand 50: 201–206Google Scholar
  171. Uytdehaag IGCM, Osterhaus ADME (1985) Induction of neutralising antibody in mice against poliovirus type II with monoclonal anti-idiotypic antibody. J Immunol 134: 1225–1229PubMedGoogle Scholar
  172. Van Etta L, Brown J, Mastri A, Wilson T (1981) Fatal vidarabine toxicity in a patient with normal renal function. JAMA 246: 1703–1705PubMedGoogle Scholar
  173. Vontver LA, Reeves WC, Rattray M et al (1979) Clinical course and diagnosis of genital herpes simplex virus infection and evaluation of topical surfactant therapy. Am J Obstet Gynecol 133: 548–554PubMedGoogle Scholar
  174. Wade C, Newton B, McLaren C, Flournoy N, Keeney RE (1982) Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation. Ann Intern Med 96: 265–269PubMedGoogle Scholar
  175. Wade JC, McLaren C, Meyers JD (1983) Frequency and significance of acyclovir-resistant herpes simplex virus isolated from marrow transplant patients receiving multiple courses treatment with acyclovir. J Infect Dis 148: 1077–1082PubMedGoogle Scholar
  176. Wade JC, Newton B, Flournoy N, Meyers JD (1984) Oral acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation. Ann Intern Med 100: 823–828PubMedGoogle Scholar
  177. Wallin J, Lernestedt JO, Ogenstad S, Lycke E (1985) Topical treatment of recurrent genital herpes infection with Forscarnet. Scand J Infect Dis 17: 165–172PubMedGoogle Scholar
  178. Watson RJ, Enquist L (1985) Genetically engineered herpes simplex virus vaccines. In: Melnick J L (ed) Progress in medical virology, vol 31. Karger, Basel pp. 84–108Google Scholar
  179. Weller IVD, Carreno V, Fowler MJF, et al (1983) Acyclovir in hepatitis B antigen-positive chronic liver disease: inhibition of viral replication and transient renal impairment with IV bolus administration. J Antimicrob Chemother 11: 223–231PubMedGoogle Scholar
  180. Whitley RJ (1988) Herpes simplex infection of the central nervous system. Am J Med 85 [suppl 2A]: 61–67PubMedGoogle Scholar
  181. Whitley RJ, Ch’ien LT, Dolin R, Galasso GJ, Alford CA Editors and the collaborative study group (1976). Adenine arabinoside therapy of herpes zoster in the immunosuppressed. NIAID collaborative antiviral study. N Engl J Med 294: 1193–1199Google Scholar
  182. Whitley RJ, Soong SJ, Dolin R, et al. (1977) Adenine arabinoside therapy of biopsy-proved herpes simplex virus encephalitis. National Institute of Allergy and Infectious Diseases collaborative antiviral study. N Engl J Med 297: 289–294Google Scholar
  183. Whitley RJ, Tucker BC, Kinkel AW, et al. (1980a) Pharmacology, tolerance and antiviral activity of vidarabine monophosphate in humans. Antimicrob Agents Chemother 18: 709–715PubMedGoogle Scholar
  184. Whitley RJ, Nahmias AJ, Soong SJ, Galasso GJ, Fleming CL, Alford CA (1980b) Vidarabine therapy of neonatal herpes simplex virus infection. Pediatrics 66: 495–501PubMedGoogle Scholar
  185. Whitley RJ, Soon SJ, Linneman C, Liu C, Pazin G, Alford CA (1982) Herpes simplex encephalitis. JAMA 247: 317–320PubMedGoogle Scholar
  186. Whitley RJ, Alford CA, Hirsch MS, et al (1986) Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med 314: 144–149PubMedGoogle Scholar
  187. Woodman CBJ, Buchan A, Fuller A, et al. (1983) Efficacy of a vaccine Ac NFU, (S-) MRC5 given after an initial clinical episode in the prevention of herpes genitalis. Br J Vener Dis 59: 311–313PubMedGoogle Scholar
  188. Young BJ, Patterson A, Ravenscroft T (1982) A randomised double blind clinical trial of acyclovir ( Zovirax) and adenine arabinoside in herpes simplex corneal ulceration. Br J Ophthalmol 66: 361–363Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • Adrian Mindel
    • 1
  1. 1.Academic Department of Genito-Urinary Medicine, James Pringle House, The Middlesex HospitalUniversity College and Middlesex School of MedicineLondonUK

Personalised recommendations